Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Q: What type of study is this?

This is a Subgroup analysis study.

Eva Domingo‐Domènech; Barbara Pro; Tim Illidge; Steven M. Horwitz; Lorenz Truemper; Swaminathan P. Iyer; Ranjana H. Advani; Nancy L. Bartlett; Jacob Haaber Christensen; Won-Seog Kim; Tatyana Feldman; Ilseung Choi; Giuseppe Gritti; David Belada; Andrei R. Shustov; Árpád Illes; Pier Luigi Zinzani; Andreas Hüttmann; Marek Trněný; Steven Le Gouill; Deepa Jagadeesh; Jonathan W. Friedberg; Meredith Little; Cassie Dong; Michelle A. Fanale; Keenan Fenton; Kerry J. Savage

doi:10.1038/s41408-025-01329-2

Key Points

The combination treatment showed significant benefits for patients with systemic anaplastic large cell lymphoma, improving overall survival rates.
Findings indicated a notable enhancement in outcomes over the 5-year follow-up period for those receiving brentuximab vedotin alongside chemotherapy.
This subgroup analysis from the ECHELON-2 study contributes valuable insights to the treatment of systemic anaplastic large cell lymphoma.
The results provide evidence of the long-term effectiveness of brentuximab vedotin in this patient population, supporting its continued use.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Subgroup analysis shows improved outcomes in patients with systemic anaplastic large cell lymphoma, indicating the efficacy of brentuximab vedotin combined with chemotherapy.

Abstract

Trial registration: ClinicalTrials.gov number: NCT01777152

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Domingo‐Domènech et al. (2025) studied this question.

synapsesocial.com/papers/68c1a76954b1d3bfb60e064a https://doi.org/10.1038/s41408-025-01329-2

View Full Paper

Ask AI

Bookmark

Share

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading